Indoco Remedies has allotted 31,850 equity shares under ESOP on 29 March 2024. Consequent to this allotment, the paid-up capital of the Company stands increased from Rs. 18,43,00,710 (consisting of 9,21,50,355 equity shares of face value of Rs. 2 each) to Rs. 18,43,64,410 (consisting of 9,21,82,205 equity shares of face value of Rs. 2 each).Powered by Capital Market - Live News

Indoco Remedies announced that its wholly owned subsidiary, Warren Remedies has commenced its commercial production on 24 March 2024 from its greenfield manufacturing facility located at Aurangabad, Maharashtra to manufacture Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs).Powered by Capital Market - Live News

Indoco Remedies is acquiring land (which was previously held by the Company on leasehold rights) admeasuring 2,860.75 square meterssituated at Plot No.18/A of Mahal Industrial Estate, Village Mulgaon, Taluka Andheri, District Mumbai Suburban from an unrelated third-party seller �Saldanha Realty and Infrastructure LLP� for the expansion plans of the Company. Accordingly, the Company executed the Indenture of Conveyance for the purchase of the aforesaid land. Powered by Capital Market - Live News

Net profit of Indoco Remedies declined 42.10% to Rs 16.30 crore in the quarter ended December 2023 as against Rs 28.15 crore during the previous quarter ended December 2022. Sales rose 11.58% to Rs 458.75 crore in the quarter ended December 2023 as against Rs 411.15 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales458.75411.15 12 OPM %13.7115.09 - PBDT55.1855.39 0 PBT30.8338.22 -19 NP16.3028.15 -42 Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 23 January 2024.Powered by Capital Market - Live News